Clinical Trials
704 trialsNCT03433183 2026-05-27
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00906893 2026-05-14
MISOGLIO
University Hospital, Bordeaux
Phase 2 Completed
NCT02308527 2026-05-12
BEACON
University of Birmingham
Phase 2 Completed
NCT04755023 2026-05-07
TEMOBIC
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05865990 2026-05-04
TUXEDO-3
MedSIR
Phase 2 Completed
NCT00253435 2026-04-28
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Completed
NCT03213678 2026-04-21
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT04481035 2026-04-21
NF1NAC
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed
NCT04817254 2026-04-17
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT03213665 2026-04-13
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02153957 2026-04-08
Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02595905 2026-04-08
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT03526250 2026-04-03
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT04301089 2026-03-11
Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT04343573 2026-02-27
Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05005845 2026-02-17
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
Phase 2 Completed
NCT04401774 2026-01-27
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02617745 2026-01-02
GLIOPLAK
Centre Henri Becquerel
Phase 2 Completed
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT05465343 2025-12-19
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Peking Union Medical College
Phase 2 Completed
NCT04738162 2025-12-10
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
Universität Münster
Phase 2 Completed
NCT04391062 2025-12-05
DOSINDYGO
University Hospital, Lille
Phase 2 Completed
NCT04503772 2025-12-04
STEP
Centre Jean Perrin
Phase 2 Completed
NCT01582269 2025-11-24
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company
Phase 2 Completed
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT01602666 2025-11-20
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT02939300 2025-11-14
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Completed
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
NCT01991977 2025-10-20
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT05608395 2025-09-25
GlioMET
Masaryk Memorial Cancer Institute
Phase 2 Completed
NCT03561870 2025-09-12
OLAGLI
Hospices Civils de Lyon
Phase 2 Completed
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT05012098 2025-08-08
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed